Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15323076 | 0.98 | HRH3 (0.62) | HRH3SMN1; SMN2NOS3NOS1NOS2 | |
| SCHEMBL15332115 | 0.94 | HRH3 (0.59) | HRH3SMN1; SMN2NOS3NOS1NOS2 | |
| SCHEMBL29113925 | 0.91 | HRH3 (0.54) | HRH3SMN1; SMN2NOS3NOS1NOS2 | |
| SCHEMBL14934917 | 0.85 | AKR1C3 (0.72) | HRH3ALDH1A1HPGDAOC3AKR1C3 | |
| SCHEMBL15467001 | 0.84 | HRH3 (0.87) | HRH3SMN1; SMN2NOS3NOS1NOS2 | |
| SCHEMBL2557827 | 0.83 | HRH3 (0.65) | HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL421728 | 0.83 | SIGMAR1 (0.55) | HRH3ALDH1A1HTT | |
| SCHEMBL1427526 | 0.81 | HRH3 (0.69) | HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL29952315 | 0.81 | HRH3 (0.69) | HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL875822 | 0.80 | NCF1 (0.60) | HRH3SMN1; SMN2NOS1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024016826-A1 | 6-POSITION SUBSTITUTED DIHYDROBENZO[E][1,2,3]OXATHIAZINE 2,2-DIOXIDE COMPOUND, PREPARATION THEREFOR, AND USE THEREOF | 杭州市第七人民医院 | 2024-01-25 | — | — | WO | claimed |
| EP-2697227-A1 | FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | Newlink Genetics Corporation (US) | 2014-02-19 | — | — | EP | claimed |
| WO-2012142237-A1 | FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | NEWLINK GENETICKS CORPORATION (US) | 2012-10-18 | — | — | WO | claimed |
| WO-2025243042-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILIN D | THE UNIVERSITY OF LIVERPOOL (GB) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025228828-A1 | CARBOXAMIDE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF VIRAL DISEASES | MERCK PATENT GMBH (DE) | 2025-11-06 | — | — | WO | disclosed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| WO-2025110699-A1 | NOVEL COMPOUND AND USE THEREOF | 주식회사 프로티어바이오텍 | 2025-05-30 | — | — | WO | disclosed |
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2025-05-29 | — | — | US | disclosed |
| CN-114026089-B | Substituted naphthalimides and uses thereof | UCL商业有限责任公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-4548919-A2 | SUBSTITUTED NAPHTHALENE DIIMIDES AND THEIR USE | UCL Business Ltd (GB) | 2025-05-07 | — | — | EP | disclosed |
| US-7601725-B2 | Thienopyrimidines useful as Aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| EP-1833816-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | Novartis AG (CH) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069788-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-07-06 | — | — | WO | disclosed |
| US-6919382-B2 | Preparation and uses of conjugated solid supports for boronic acids | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2005-07-19 | — | — | US | disclosed |
| EP-1230224-B1 | SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES | BASILEA PHARMACEUTICA AG (CH) | 2004-12-29 | — | — | EP | disclosed |
| US-6821980-B1 | Substituted 5-benzyl-2,4-diaminopyrimidines | BASILEA PHARMACEUTICA AG (CH) | 2004-11-23 | — | — | US | disclosed |
| US-20030044840-A1 | Preparation and uses of conjugated solid supports for boronic acids | GOVERNORS OF THE UNIVERSITY OF ALBERTA, THE (CA) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | HRH3 3648/4885SMN1; SMN2 3836/4885NOS3 1621/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | HRH3 251/4885SMN1; SMN2 2563/4885NOS3 2276/4885 |
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | HRH3 756/4885SMN1; SMN2 3994/4885NOS3 2583/4885 |
| US-20030044840-A1 | Preparation and uses of conjugated solid supports for boronic acids | SLC43A1, SBDS, SLC7A5 | HRH3 283/4885SMN1; SMN2 3648/4885NOS3 3780/4885 |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | HRH3 977/4885SMN1; SMN2 3064/4885NOS3 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.